Clinical Trial Update: LDL-C Optimization Using Inclisiran in Patients in Which Drug-Drug Interactions Limit LDL Lowering [Phase 4]

View source ↗

Summary

Phase 4 clinical trial updating LDL-C optimization with inclisiran for patients in whom drug-drug interactions limit LDL lowering; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerotic Cardiovascular Disease
• Cardiometabolic Syndrome
• Hyperlipidemia

Drugs mentioned

• LEQVIO (inclisiran)

Snippet

Sponsor: University of California, San Diego | Conditions: Drug Interactions, Primary Prevention | Phase 4 | Status: RECRUITING